Role of omalizumab in allergic mediated diseases

Speciality: Pulmonary Medicine

Description:

A warm welcome to all the medical professionals in this interesting session on Role of omalizumab in allergic mediated diseases
Omalizumab, a monoclonal antibody, plays a crucial role in the management of allergic-mediated diseases by targeting immunoglobulin E (IgE), a key molecule in the allergic response. Originally developed for treating moderate to severe allergic asthma, omalizumab works by binding to free IgE in the bloodstream, preventing it from attaching to immune cells and triggering the release of inflammatory substances that cause asthma symptoms. This mechanism helps reduce the frequency and severity of asthma attacks, improving lung function and quality of life for patients who are inadequately controlled by standard therapies.
Beyond asthma, omalizumab has shown efficacy in other allergic-mediated conditions, such as chronic spontaneous urticaria (CSU) and nasal polyps. In CSU, a condition characterized by persistent hives and itching, omalizumab significantly reduces symptoms and provides relief for patients who do not respond to antihistamines. Its role in treating nasal polyps, especially in patients with co-existing asthma, has also been recognized, helping to reduce polyp size and improve nasal airflow.
Therefore, get an overall knowledge of role of omalizumab in allergic mediated diseases
 

See More Webinars @ Hidoc Webinars